Oragenics to Showcase Concussion Treatment Progress at Nasal Innovation Forum
Event summary
- Oragenics' Chief Medical Officer James P. Kelly to present at IPAC-RS 2026 Nasal Innovation Forum on September 17, 2026.
- Presentation to focus on ONP-002 intranasal delivery platform for concussion treatment, including Phase IIa trial design.
- ONP-002 Phase IIa feasibility trial currently enrolling at three sites in Australia.
- Company anticipates IND submission for U.S. development in Q4 2026.
The big picture
Oragenics' presentation at the IPAC-RS forum highlights the growing interest in nasal drug delivery for neurological conditions, particularly where traditional delivery methods fall short. The company's focus on concussion treatment addresses a significant unmet medical need, with no FDA-approved pharmacological options currently available. The strategic emphasis on direct brain delivery via proprietary technology could differentiate Oragenics in the competitive landscape of neuroprotective therapies.
What we're watching
- Clinical Progress
- The pace at which ONP-002 Phase IIa trial in Australia completes enrollment and yields preliminary data.
- Regulatory Pathway
- Whether Oragenics' IND submission in Q4 2026 meets FDA expectations for U.S. clinical development.
- Market Opportunity
- How successful case studies at the forum position Oragenics' intranasal delivery platform for broader neurological applications.
Related topics